Nov 20, 2025 | Legal Compliance
In response to COVID–19 on January 31, 2020, the DEA granted temporary exceptions to the Ryan Haight Act and the DEA’s regulations under 21 U.S.C. 802(54)(D). For nearly six years, those flexibilities have remained in place through a series of temporary rules. If...
Nov 4, 2025 | Legal Compliance
If you’ve ever noticed that nursing board investigations, pharmacy board visits, or surprise regulatory inspections often happen at the end of the week, you’re not imagining it. At Lengea Law, we’ve represented thousands of aesthetic providers, nurses, NPs, PAs, and...
Oct 20, 2025 | Legal Compliance
The FDA recently issued warning letters to six companies, five in the U.S. and one in Germany, for selling compounded versions of retatrutide, an experimental weight-loss drug that is not yet approved for public use. The agency’s message is straightforward:...
Oct 20, 2025 | Legal Compliance
As the medical aesthetics and wellness industry continues to expand, compounded products, from peptides and hormones to injectables, have become commonplace in medspas and functional medicine practices. However, the FDA has issued a strong warning: certain bulk drug...
Oct 20, 2025 | Legal Compliance
In a closely watched case involving compounded GLP-1 drugs, a federal judge in Delaware has dismissed Eli Lilly’s lawsuit against Strive Pharmacy, sending a clear message: national pharma litigation doesn’t override basic jurisdictional rules. Lilly alleged Strive...
Sep 13, 2025 | Legal Compliance, Risk Management, State-Specific Regulations
Cal/OSHA has released its revised Safety and Health Protection on the Job poster, effective July 2025. California employers must display the updated notice in a clearly visible location. Failure to post it, or to comply with the rules it summarizes, can lead to...
